Amy S. Kimball
Amy S. Kimball, M.D., Ph.D. is a member of the Tumor Immunology and Immunotherapy Program within the University of Maryland Marlene and Stuart Greenebaum Cancer Center Program in Oncology (UMGCC). Dr. Kimball joined UMGCC in 2009. Dr. Kimball was an undergraduate at University of California Santa Cruz, graduating in 1985. In 1990 she completed a Ph.D. at Johns Hopkins School of Arts and Sciences where she studied DNA structure in the laboratory of Dr. Thomas Tullius. She then was awarded an NIH postdoctoral fellowship to study DNA replication in Dr. Roger McMacken’s laboratory. In 2002 Dr. Kimball graduated from the University of Maryland School of Medicine. After residency and a year as Chief resident at Sinai Hospital in Baltimore Dr. Kimball returned to University of Maryland for Fellowship training in Hematology and Oncology which she completed in 2009.
Dr. Kimball's clinical interest is in lymphoma. She cares for newly diagnosed, and relapsed, patients with Hodgkin and NonHodgkin Lymphoma, including Diffuse Large B-cell, Follicular, Mantle Cell, and Marginal Zone Lymphomas, as well as T-cell lymphomas and CLL. Dr. Kimball has a variety of clinical trials open, offering novel therapies to lymphoma patients.
Dr. Kimball enjoys active research collaborations with University of Maryland investigators. Within the Tumor Immunology and Immunotherapy Program (TII), she works with members of the Webb laboratory to investigate mechanisms of immune suppression in lymphoma patients. She is characterizing signaling pathways in Hodgkin lymphoma with members of the Davila group, also in the TII Program.
Dr. Kimball studies Adult T-cell leukemia/lymphoma with UMGCC clinical collaborators and investigators from the Institute of Human Virology (Population Science Program). She also appreciates evaluating imaging studies in lymphoma with Dr. Wengen Chen from the Department of Nuclear Medicine.
- Hodgkin Lymphoma
- Diffuse Large B-cell lymphoma
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma
- Peripheral T-cell lymphoma
- Adult T-cell Leukemia/lymphoma
- Chronic Lymphocytic Leukemia
- J.Li, W.Sun, P.B.Subrahmanyam, C.Page, K.M.Younger, I.V.Tiper, M.Frieman, A.S.Kimball, T.J.Webb (2014). NKT cell responses to B cell lymphoma. Med.Sci 2, 82-97. PubMedID 24955274
- J. Kim, W.Chen, C.Resnik, V.Dilsizian, Q.Chen and A.S.Kimball (2014). FDG Uptake in Liposclerosing Myxofibrous Tumor Causes Upstaging of Hodgkin Lymphoma. Clin Nucl Med. PMID 25290293
- A. Kimball, J.Collins and R.Scilla (2014). A 56-Year-Old Female with Unintentional Weight Loss. Am J Med Sci. PMID: 25079339
- A.S.Kimball and T.J.Webb (2013). The Roles of Radiotherapy and Immunotherapy for the Treatment of Lymphoma. Mol Cell Pharmacol 5(1):27-38. PMID: 24648864
- Y.Ning, A.Foss, A.S.Kimball, N. Neill, T. Matz, K. Schultz, (2013). Characterization of a case of folliclar lymphoma transformed into B-lymphoblastic leukemia. Molec Cytogenet. 6(1):24. PMID: 23985173
- J.Yared, A.Kimball, M.R.Baer, H.Bahrain and M.Auerbach. (2013) Rituximab maintenance therapy until progression after rituximab and chemotherapy induction in patients with follicular lymphoma. Clin Lymphoma Myeloma Leuk. 13(3): 253-7.
- J.Yared, A.Kimball. (2013). The role of high dose chemotherapy and autologous stem-cell transplantation in peripheral T-cell lymphoma: A review of the literature and new perspectives. Cancer Treatment Reviews 39(1): 51-9.
- C.Morrison, M.R.Baer, D.P.Zandberg, A.Kimball and E. Davila (2011) Effects of Toll-like Receptor Signals in T-Cell Neoplasms. Future Oncology 7(2), 309-320.
- A.Kimball, M.L.Kimball, M.Jayaram, and T.D.Tullius (1995) Chemical probe and missing nucleotide analysis of Flp recombinase bound to recombination target sequence. Nucl. Acids Res. 23, 3009-3017.
- A.Kimball, J.Lee, M.Jayaram, and T.D.Tullius (1993). Sequence Specific cleavage of DNA via nucleophilic attack of hydrogen peroxide, assisted by Flp recombinase, Biochem. 32, 4698-4701.
- A.Kimball, Q.Guo, M.Lu, R.P.Cunningham, N.R.Kallenbach, N.C.Seeman and T.D.Tullius, (1990) Construction and analysis of Parallel and Antiparallel Holliday junctions, J. Biol. Chem. 265, 6544-6547.
- A.Kimball, G.Milman and T.D.Tullius (1989) High Resolution Footprints of the DNA binding domain of Epstein Barr Virus Nuclear Antigen-1 Mol. Cell. Bio. 9, 2738-2742.
- J.K.Jasielec, A.S.Kimball,K.S.Cohen, J.P.Kline, A.P.Rapoport, A.M.Petrich, S.P.Thomas, C.Nabhan, L.A.Doyle, W.M.Stadler, T.Karrison, and S.M.Smith. (2014) Temsirolimus and Lenalidomide in Relapsed/Refractory Hodgkin Lymphoma including in Patients with prior exposure to Brentuximab Vedotin: Results from a Phase II Study (NCI8309). JCO 32:5s, Abstract #8567.
- S.M.Smith, K.Cohen, J.Kline, J.Zavala, K.Conner, S.Thomas, P.Lesho, L. A Doyle, W.Stadler, A.Kimball. (2012) Phase I Trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas. JCO 30, Abstract #8075
- B.Holkova, E.B.Perkins, L.Sokol, K.L.Richards, S.Parekh, R.Elstrom, A.Z.Badros, I. Espinoza-Delgado, M.J.Schell, A.Kimball, M.Tombes, E.Schrader, H.Sankala, D.Coppola, M. Kmieciak, D.Sullivan, J.D.Roberts, and S.Grant. (2011) A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymhpoma and Diffuse Large B-Cell Lymphoma, (ASH Annual Meeting Abstracts) 118:779